Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein
- PMID: 25819327
- PMCID: PMC4456247
- DOI: 10.1016/j.coviro.2015.03.002
Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein
Abstract
Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis, but despite decades of research a safe and effective vaccine has remained elusive. The viral fusion glycoprotein (RSV F) plays an obligatory role in the entry process and is the major target of neutralizing antibodies, making it an attractive target for vaccine development. This review will summarize the recently determined structures of RSV F in the prefusion and postfusion conformations and describe the location and properties of neutralizing epitopes on RSV F, including the newly identified prefusion-specific epitopes. The influence of these findings on vaccine development will also be discussed, with a focus on the rational design and optimization of vaccine antigens.
Copyright © 2015 Elsevier B.V. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4456247/bin/nihms-671459-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4456247/bin/nihms-671459-f0002.gif)
Similar articles
-
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses.J Virol. 2016 May 12;90(11):5485-5498. doi: 10.1128/JVI.00338-16. Print 2016 Jun 1. J Virol. 2016. PMID: 27009962 Free PMC article.
-
Novel Respiratory Syncytial Virus-Like Particle Vaccine Composed of the Postfusion and Prefusion Conformations of the F Glycoprotein.Clin Vaccine Immunol. 2016 Jun 6;23(6):451-9. doi: 10.1128/CVI.00720-15. Print 2016 Jun. Clin Vaccine Immunol. 2016. PMID: 27030590 Free PMC article.
-
Design and characterization of a fusion glycoprotein vaccine for Respiratory Syncytial Virus with improved stability.Vaccine. 2018 Dec 18;36(52):8119-8130. doi: 10.1016/j.vaccine.2018.10.032. Epub 2018 Oct 16. Vaccine. 2018. PMID: 30340881
-
Influence of antigen conformation and mode of presentation on the antibody and protective responses against human respiratory syncytial virus: relevance for vaccine development.Expert Rev Vaccines. 2016 Oct;15(10):1319-25. doi: 10.1080/14760584.2016.1175941. Epub 2016 Apr 22. Expert Rev Vaccines. 2016. PMID: 27055009 Review.
-
Vaccine development for respiratory syncytial virus.Curr Opin Virol. 2017 Apr;23:107-112. doi: 10.1016/j.coviro.2017.03.012. Epub 2017 May 16. Curr Opin Virol. 2017. PMID: 28525878 Free PMC article. Review.
Cited by
-
Detailed analysis of low temperature inactivation of respiratory syncytial virus.Sci Rep. 2024 May 23;14(1):11823. doi: 10.1038/s41598-024-62658-z. Sci Rep. 2024. PMID: 38783052 Free PMC article.
-
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults.Vaccine X. 2024 Apr 27;18:100494. doi: 10.1016/j.jvacx.2024.100494. eCollection 2024 Jun. Vaccine X. 2024. PMID: 38746060 Free PMC article.
-
Resurgence of respiratory syncytial virus with dominance of RSV-B during the 2022-2023 season.Front Microbiol. 2024 Apr 2;15:1376389. doi: 10.3389/fmicb.2024.1376389. eCollection 2024. Front Microbiol. 2024. PMID: 38628867 Free PMC article.
-
Engineered dityrosine-bonding of the RSV prefusion F protein imparts stability and potency advantages.Nat Commun. 2024 Mar 14;15(1):2202. doi: 10.1038/s41467-024-46295-8. Nat Commun. 2024. PMID: 38485927 Free PMC article.
-
Characterization of a Panel of Monoclonal Antibodies Targeting the F-Protein of the Respiratory Syncytial Virus (RSV) for the Typing of Contemporary Circulating Strains.Trop Med Infect Dis. 2023 Dec 19;9(1):1. doi: 10.3390/tropicalmed9010001. Trop Med Infect Dis. 2023. PMID: 38276631 Free PMC article.
References
-
- Hall CB, Simoes EA, Anderson LJ. Clinical and epidemiologic features of respiratory syncytial virus. Curr Top Microbiol Immunol. 2013;372:39–57. - PubMed
-
- Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child. 1986;140:543–546. - PubMed
-
- Hall CB. The burgeoning burden of respiratory syncytial virus among children. Infect Disord Drug Targets. 2012;12:92–97. - PubMed
-
- Hall CB, Weinberg GA, Blumkin AK, Edwards KM, Staat MA, Schultz AF, Poehling KA, Szilagyi PG, Griffin MR, Williams JV, et al. Respiratory syncytial virus-associated hospitalizations among children less than 24 months of age. Pediatrics. 2013;132:e341–348. - PubMed
-
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2013;380:2095–2128. - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources